D
IDEAYA Biosciences, Inc.
IDYA
$19.13
$0.552.96%
D
Sell
3/14/2023Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
3/8/2023Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D from D+ on 3/8/2023 due to a large decline in the growth index, solvency index and valuation index. EBIT declined 4,106.52% from $660 to -$26.44M, earnings per share declined from $0.04 to -$0.5062, and total revenue declined 86.46% from $29.7M to $4.02M.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D from D+ on 3/8/2023 due to a large decline in the growth index, solvency index and valuation index. EBIT declined 4,106.52% from $660 to -$26.44M, earnings per share declined from $0.04 to -$0.5062, and total revenue declined 86.46% from $29.7M to $4.02M.
D
Sell
2/9/2023Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D- on 2/9/2023 due to an increase in the volatility index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D- on 2/9/2023 due to an increase in the volatility index.
D
Sell
2/8/2023Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D+ on 02/08/2023.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D+ on 02/08/2023.
D
Sell
11/10/2022Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D on 11/10/2022 due to a substantial increase in the growth index, solvency index and volatility index. Total revenue increased 407.59% from $5.85M to $29.7M, the quick ratio increased from 4.63 to 11.91, and earnings per share increased from -$0.5705 to $0.04.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D on 11/10/2022 due to a substantial increase in the growth index, solvency index and volatility index. Total revenue increased 407.59% from $5.85M to $29.7M, the quick ratio increased from 4.63 to 11.91, and earnings per share increased from -$0.5705 to $0.04.
D
Sell
8/16/2022Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D from D+ on 8/16/2022 due to a substantial decline in the growth index and solvency index. EBIT declined 58.22% from -$14.22M to -$22.5M, earnings per share declined from -$0.3631 to -$0.5705, and total revenue declined 48.49% from $11.36M to $5.85M.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D from D+ on 8/16/2022 due to a substantial decline in the growth index and solvency index. EBIT declined 58.22% from -$14.22M to -$22.5M, earnings per share declined from -$0.3631 to -$0.5705, and total revenue declined 48.49% from $11.36M to $5.85M.
D
Sell
7/22/2022Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D on 7/22/2022 due to an increase in the volatility index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D on 7/22/2022 due to an increase in the volatility index.
D
Sell
7/7/2022Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D from D+ on 7/7/2022 due to a decline in the volatility index and valuation index.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D from D+ on 7/7/2022 due to a decline in the volatility index and valuation index.
D
Sell
6/17/2022Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D on 6/17/2022 due to an increase in the volatility index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D on 6/17/2022 due to an increase in the volatility index.
D
Sell
5/31/2022Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
D
Sell
5/13/2022Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and total return index. The quick ratio declined from 5.49 to 4.45.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and total return index. The quick ratio declined from 5.49 to 4.45.
D
Sell
5/5/2022Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D from D- on 05/05/2022.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D on 4/20/2022 due to a decline in the volatility index and total return index.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
3/25/2022Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D from D+ on 3/25/2022 due to a substantial decline in the growth index, total return index and volatility index. Total revenue declined 67% from $8.98M to $2.96M, EBIT declined 56.83% from -$11.71M to -$18.37M, and earnings per share declined from -$0.3066 to -$0.473.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D from D+ on 3/25/2022 due to a substantial decline in the growth index, total return index and volatility index. Total revenue declined 67% from $8.98M to $2.96M, EBIT declined 56.83% from -$11.71M to -$18.37M, and earnings per share declined from -$0.3066 to -$0.473.
D
Sell
11/9/2021Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D- on 11/9/2021 due to an increase in the total return index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D- on 11/9/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D+ on 11/8/2021 due to a decline in the valuation index.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to D- from D+ on 11/8/2021 due to a decline in the valuation index.
D
Sell
12/1/2020Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D on 12/1/2020 due to a significant increase in the total return index, growth index and solvency index. Operating cash flow increased 763.02% from -$13.61M to $90.21M, earnings per share increased from -$0.59 to -$0.1735, and EBIT increased 60.32% from -$12.59M to -$5M.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D+ from D on 12/1/2020 due to a significant increase in the total return index, growth index and solvency index. Operating cash flow increased 763.02% from -$13.61M to $90.21M, earnings per share increased from -$0.59 to -$0.1735, and EBIT increased 60.32% from -$12.59M to -$5M.
D
Sell
6/16/2020Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D from D- on 6/16/2020 due to an increase in the volatility index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D from D- on 6/16/2020 due to an increase in the volatility index.
D
Sell
2/4/2020Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D- from E on 2/4/2020 due to an increase in the volatility index and total return index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to D- from E on 2/4/2020 due to an increase in the volatility index and total return index.
E
Sell
1/30/2020Downgrade
IDEAYA Biosciences, Inc. (IDYA) was downgraded to E from E+ on 1/30/2020 due to a decline in the volatility index.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to E from E+ on 1/30/2020 due to a decline in the volatility index.
E
Sell
1/15/2020Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to E+ from E on 1/15/2020 due to an increase in the volatility index and total return index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to E+ from E on 1/15/2020 due to an increase in the volatility index and total return index.
E
Sell
11/5/2019Upgraded
IDEAYA Biosciences, Inc. (IDYA) was upgraded to E from E- on 11/5/2019 due to an increase in the total return index.
IDEAYA Biosciences, Inc. (IDYA) was upgraded to E from E- on 11/5/2019 due to an increase in the total return index.
E
Sell
8/19/2019None
IDEAYA Biosciences, Inc. (IDYA) was downgraded to E- from U on 08/19/2019.
IDEAYA Biosciences, Inc. (IDYA) was downgraded to E- from U on 08/19/2019.
NASDAQ
03/17/2025 4:00PM Eastern
Quotes delayed
